How to buy Cellectis stock (CLLS)

Cellectis is a biotechnology business based in the US. Cellectis shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.64 – a decrease of 6.82% over the previous week. Cellectis employs 216 staff and has a trailing 12-month revenue of around $36 million.

Our top picks for where to buy Cellectis stock

Buy Cellectis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cellectis stock price (NASDAQ: CLLS)

Use our graph to track the performance of CLLS stocks over time.

Cellectis shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.64
52-week range	$1.58 - $3.55
50-day moving average more info button	$1.90
200-day moving average more info button	$2.27
Wall St. target price	$6.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.16

Is it a good time to buy Cellectis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectis price performance over time

Historical closes compared with the close of $1.59 from 2024-12-19

1 week (2024-12-13)	-9.66%
1 month (2024-11-21)	-14.52%
3 months (2024-09-20)	-29.55%
6 months (2024-06-21)	-15.87%

1 year (2023-12-21)	-52.82%
2 years (2022-12-21)	-21.29%
3 years (2021-12-21)	8.41
5 years (2019-12-20)	18.11

Cellectis financials

Revenue TTM	$36 million
Gross profit TTM	$24 million
Return on assets TTM	-16.09%
Return on equity TTM	-82.2%
Profit margin	-234.39%
Book value	$1.29
Market Capitalization more info button	$167.4 million

TTM: trailing 12 months

Cellectis share dividends

We're not expecting Cellectis to pay a dividend over the next 12 months.

Cellectis share price volatility

Over the last 12 months, Cellectis's shares have ranged in value from as little as $1.5803 up to $3.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis's is 3.2. This would suggest that Cellectis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cellectis overview

Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.

Frequently asked questions

null
What percentage of Cellectis is owned by insiders or institutions?
Currently 3.866% of Cellectis shares are held by insiders and 16.649% by institutions. How many people work for Cellectis?
Latest data suggests 216 work at Cellectis. When does the fiscal year end for Cellectis?
Cellectis's fiscal year ends in December. Where is Cellectis based?
Cellectis's address is: 8, rue de la Croix Jarry, Paris, France, 75013 What is Cellectis's ISIN number?
Cellectis's international securities identification number is: US15117K1034 What is Cellectis's CUSIP number?
Cellectis's Committee on Uniform Securities Identification Procedures number is: 15117K103